Aptorum Group Limited (NASDAQ:APM) Short Interest Update

Aptorum Group Limited (NASDAQ:APM) saw a significant increase in short interest in June. As of June 15th, there was short interest totaling 101,658 shares, an increase of 3,995.8% from the May 31st total of 2,482 shares. Based on an average daily trading volume, of 583,559 shares, the short-interest ratio is presently 0.2 days. Approximately 4.4% of the shares of the stock are short sold.

Aptorum Group Stock Down 4.5%

Aptorum Group stock traded down $0.04 during trading hours on Thursday, hitting $0.78. The stock had a trading volume of 50,933 shares, compared to its average volume of 370,185. Aptorum Group has a 1-year low of $0.65 and a 1-year high of $4.47. The stock’s fifty day moving average is $0.89 and its two-hundred day moving average is $0.94.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Aptorum Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Aptorum Group Company Profile

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.